Hilly Paige Shares Key Takeaways from 2025 ESC/EAS Cholesterol Guideline
Hilly Paige, Chief Innovation Officer at the Family Heart Foundation, has shared a post on LinkedIn:
“Great overview by Family Heart Foundation of the new cholesterol guidelines from European Society of Cardiology and European Atherosclerosis Society.
Figure 2 from the 2025 update is superb. Combinations of proven therapies can lower LDL-C by up to 86%! With so many safe and effective therapies available in the toolbox, it is unacceptable that currently <30% of high-risk individuals are achieving their LDL-C goals!
Also, great to see two important LDL-C lowering therapies included in the 2025 update – bempedoic acid from Esperion and evinacumab from Regeneron!
Finally, using supplements to lower your LDL-C? Don’t waste your money.”
Check here for more information.
Stay informed with Hemostasis Today.
-
Sep 23, 2026, 16:04Monia Ezzalfani: Advancing Patient-Centered Care in Hemophilia A and B
-
Sep 23, 2026, 15:49Bilge Başak: How Activated PRP Modulates Osteoarthritic Chondrocyte Function
-
Sep 23, 2026, 14:50Mbonjo Bitsie Dora: Strengthening Sickle Cell Care Through Education, Awareness and Innovation
-
Sep 23, 2026, 13:58The New B12 Diagnostic Algorithm: From Serum Cobalamin to Functional Deficiency
-
Sep 23, 2026, 13:56Noha Soror: Preparing for Hematology and Medical Oncology Board Certification
-
Sep 23, 2026, 13:46Ugochi Ogu: What Can Platelet Proteomics Reveal about Pain and Neurocognitive Vulnerability in Sickle Cell Disease?
-
Sep 23, 2026, 13:42Melissa Hollo: Connecting Obesity and Anemia for Earlier Maternal Risk Intervention
-
Sep 23, 2026, 13:16Beverley Hunt: Advances in Haemostatic Management of Postpartum Haemorrhage
-
Sep 23, 2026, 13:13Ioanna Mela: Recruiting a Research Associate on DNA nanotechnology